Advertisement

 

 

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.

Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns.
Author Information (click to view)

Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE,


Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE, (click to view)

Braun HM, Candelario J, Hanlon CL, Segura ER, Clark JL, Currier JS, Lake JE,

Advertisement

LGBT health 2017 09 06() doi 10.1089/lgbt.2017.0057

Abstract
PURPOSE
Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence.

METHODS
This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA.

RESULTS
Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns.

CONCLUSION
Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

Submit a Comment

Your email address will not be published. Required fields are marked *

10 + 11 =

[ HIDE/SHOW ]